Aptar Pharma said this week that its Bidose nasal spray device won FDA approval for use with a breakthrough depression therapy.
The Crystal Lake, Ill.-based company’s Bidose tech enables two-shot nasal drug delivery. Aptar touted its manufacturing facility in Congers, NY, which supports the manufacture of nasal and injectable drug delivery systems.
Get the full story at our sister site, Drug Delivery Business News.
The post Aptar Pharma touts FDA approval of nasal spray device appeared first on MassDevice.
from MassDevice https://ift.tt/2Wa3Bx6
Cap comentari:
Publica un comentari a l'entrada